Gamida Cell Ltd.

Gamida Cell Ltd.

Gamida Cell Ltd.

Overview
Date Founded

1998

Headquarters

5 Nahum Hafzadi Street,Givaat Shaul,Jerusalem 91340

Type of Company

Public

Employees (Worldwide)

112

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology
Medical Products & Equipment

Company Description

Gamida Cell Ltd. operates as a clinical stage biopharmaceutical company. It engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

Contact Data
Trying to get in touch with decision makers at Gamida Cell Ltd.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer

Vice President, Finance & Operations

Chief Operating & Commercial Officer

Chief Scientific Officer

Chief Regulatory & Quality Officer

Chief Business Officer

Chief Manufacturing Officer

Chief Medical Officer

Vice President, Market Access

Board of Directors

Director, President & Chief Executive Officer at Cytokinetics, Inc.

Partner at Kirkland & Ellis LLP

Former Executive Vice President, Chief Financial Officer & Chief Operating Officer at Palatin Technologies Inc.

Chief Executive Officer & Executive Director at AVITA Medical, Inc.

Chief Executive Officer at Gamida Cell Ltd.

Former Chief Commercial Officer at Pharmacyclics LLC

Chief Financial Officer at Crazy Labs Ltd.

Chief Executive Officer at Clal Biotechnology Industries Ltd.

Faculty Affiliate, Department of Medical Ethics at New York University - School of Medicine

Managing General Partner & Co-Founder at Peregrine Ventures Management Ltd.

Paths to Gamida Cell Ltd.
Potential Connections via
Relationship Science
You
Gamida Cell Ltd.
Owners & Shareholders
Details Hidden

Consonance Capital aims to deliver exceptional, uncorrelated risk-adjusted returns through investment opportunities in the publicly traded stocks of healthcare companies. The firm seeks to meet this strategy by investing in publicly traded micro-cap, small-cap and mid-cap healthcare equities. They believe the public healthcare market lends itself to an active long/short strategy. Consonance Capital is focused on creating long and short portfolios driven by the opportunity for absolute return and alpha creation. The firm seeks to identify and analyze companies trading below their intrinsic value, which may include deep value as well as growth companies.

Details Hidden

Stonepine Capital Management focuses primarily, but not exclusively, on equity and equity-related securities in US publicly healthcare companies. The firm seeks to invest in companies whose valuations reflect a material discount to their fundamental value in the healthcare space. Stonepine typically prefers to invest in companies at a price reflecting a discount to current commercial and financial assets alone.The Stonepine Funds’ investment objective is to achieve superior absolute returns while preserving capital. They have formed Special Purpose Vehicles (SPVs) whose investment objective may differ because these investments tend to be more concentrated than the Stonepine Funds. Stonepine seeks to achieve their investment objective primarily by investing assets in publicly traded healthcare companies. Stonepine's investment focus is companies with commercial stage products generating sustainable revenue and companies with substantial financial assets (such as cash and royalty income streams).

Details Hidden

McAdam tailors its advisory services to meet the needs of its individual clients and seeks to manage client portfolios in a manner consistent with those needs and objectives. The firm primarily allocates client assets among various mutual funds, ETFs, individual debt and equity securities, and independent investment managers in accordance with their stated investment objectives. In addition, they may also recommend that certain eligible clients invest in privately placed securities, which may include debt, equity and/or interests in pooled investment vehicles.

Recent Transactions
Details Hidden

Gamida Cell Ltd. issued USD Ordinary Shares

Details Hidden

Gamida Cell Ltd. issued USD Ordinary Shares

Details Hidden

Gamida Cell Ltd. issued USD Ordinary Shares

Transaction Advisors
Escrow Agent

Advised onGamida Cell Ltd. issued USD Ordinary Shares

Underwriter

Advised onGamida Cell Ltd. issued USD Ordinary Shares

Auditor

Advised onGamida Cell Ltd. issued USD Ordinary Shares

Legal Advisor

Advised onGamida Cell Ltd. issued USD Ordinary Shares

Managing Director

Advised onGamida Cell Ltd. issued USD Ordinary Shares

Legal Advisor

Advised onGamida Cell Ltd. issued USD Ordinary Shares

Advisors & Consultants
Legal Advisor

Partner, New York at Cooley LLP

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Key Stats and Financials As of 2020
Market Capitalization
$342M
Total Enterprise Value
$247M
Earnings Per Share
$-1.66
Revenue
$0
Net Profit
$-72.7M
EBITDA
$-60.4M
Total Debt
$7.91M
Total Equity
$98.7M
TEVNet Income
-3.4x
Debt TEV
0.03x
Three Year Compounded Annual Growth Rate Of Revenue
0%
Investors
Details Hidden

FMR help over 32 million people feel more confident in their most important financial goals, manage employee benefit programs for over 22,000 businesses, and support more than 13,000 financial institutions with innovative investment and technology solutions to grow their businesses.

Details Hidden

Auriga is an active manager which invests in start-up companies in the IT and life science sectors. The firm invests primarily in the European Union, with a minor focus on North America and Israel. For investments outside of France, they participate in the funding with their global network of local venture capital investors.Auriga generally invests a minimum of 1 million euros, with an average of 5 million euros for the overall investment. The firm raises capital through substantial financing rounds involving other investors, aiming to invest in companies with an outstanding management team, a sharp differentiating factor, a large market, a viable business model and potential for capital gain.Auriga specializes in taking minority equity stakes in their investee companies, working in partnership to develop and solidify the executive team, organize the company and form strategic and corporate partnerships. In addition, the firm actively contributes to defining the investee firm's appropriate financial strategy and assisting them in raising future capital.

Details Hidden

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Suppliers
Miltenyi GmbH Medical Products & Equipment | Teterow, Germany

Miltenyi Biotec GmbH provides biotechnology products and services. The firm products include MACS sample preparation, MACS cell separation, MACS flow cytometry, MACS cell culture and stimulation and MACS molecular; research areas include immunology, stem cell research, neuroscience, and cancer research. Its clinical applications include clinical development, CliniMACS system, MACS GMP products, CryoMACS freezing products, TheraSorb, graft engineering, immunotherapy, tissue regeneration and freezing products. The company was founded by Stefan Miltenyi in 1989 and is headquartered in Teterow, Germany.

Lonza Group AG Pharmaceuticals | Basel, Che

Lonza Group AG engages in the supply of pharmaceutical, healthcare and life science products. It operates through the following segments: Lonza Pharma Biotech & Nutrition and Lonza Specialty Ingredients. The Pharma Biotech & Nutrition segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems. The Lonza Specialty Ingredients segment consists of two divisions, consumer health and consumer resources and protection. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Competitors
United Therapeutics Corp. Pharmaceuticals - Silver Spring, Maryland

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It also involves in the research and development of new indications and delivery devices for its product and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Agilent Technologies, Inc. Industrial Machinery & Manufacturing - Santa Clara, CA

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets; Diagnostics and Genomics; and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Bristol-Myers Squibb Company Pharmaceuticals - New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Gamida Cell Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Gamida Cell Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Gamida Cell Ltd..